Home
18.5.8 Biomarkers of e-cigarette exposure
Foreword

Suggested citation

Download Citation
Winnall, WR. 18.5.8 Biomarkers of e-cigarette exposure. In Greenhalgh, EM|Scollo, MM|Winstanley, MH [editors]. Tobacco in Australia: Facts and issues. Melbourne : Cancer Council Victoria; 2019. Available from https://www.tobaccoinaustralia.org.au/chapter-18-e-cigarettes/18-5-chemicals-in-e-liquids-and-e-cigarette-aerosols/18-5-8-biomarkers-of-e-cigarette-exposure
Last updated: June 2026

18.5.8 Biomarkers of e-cigarette exposure

The section describes the biomarkers used to detect exposure to specific chemicals found in e-cigarettes, under these subsections:

Biomarkers of nicotine exposure

Biomarkers of volatile organic compounds

Biomarkers of toxic metal/metalloid exposure

Biomarkers of N-nitrosamine exposure

Biomarkers for e-cigarette aerosols are substances in the human body that can be measured in a test that will indicate exposure to specific chemicals from e-cigarettes. Biomarkers of e-cigarette exposure can be detected in samples such as saliva and urine. They can indicate the dose of a specific chemical exposure, the biological activity, damage or potential for damage and the risk of disease.1 A drawback of using biomarkers to examine exposure is that other potential source of these chemicals, such as pollution, may have contributed to the presence of the chemical. See Section 12.5.6 for more information about biomarkers.

This subsection describes biomarkers of exposure to specific chemicals in e-cigarettes. Biomarkers of damage or disease, such as DNA damage, are discussed in relevant parts of Section 18.6.

A 2021 scoping review evaluated biomarker levels and compared exposure among people who smoked, used e-cigarettes or used neither.2 This review found consistent evidence suggesting that biomarkers of some volatile organic compounds (VOCs) (acrylamide and acrylonitrile), metals (beryllium, cadmium, selenium, uranium and zinc) and propylene glycol are higher in e-cigarette users compared with non-users. However, conflicting data meant that it is was unclear whether e-cigarette users have similar or higher biomarkers of acrolein, benzene, crotonaldehyde, formaldehyde, propylene oxide, toluene, xylene and 1,3-butadiene, and some metals (chromium, lead, nickel, strontium and manganese) compared to non-users.2

In comparisons of e-cigarette-only users to people who smoke conventional cigarettes only: biomarkers of VOCs (acrolein, acrylamide, acrylonitrile, ethylene oxide, vinyl chloride and 1,3-butadiene) were lower in e-cigarette users. However, use of e-cigarette users or cigarette lead to similar urinary levels of beryllium, zinc and uranium. There were insufficient data to draw conclusions on the levels of biomarkers for other VOCs (benzene, crotonaldehyde and propylene oxide) and metals (cadmium, chromium, lead, nickel, manganese and strontium).2

18.5.8.1 Biomarkers of nicotine exposure

In humans, nicotine is converted into cotinine, which has a longer half-life and is a useful biomarker for nicotine exposure. E-cigarette users have higher levels of cotinine compared to people who don’t smoke or use cigarettes. However, numerous studies have found that e-cigarette users have similar levels of cotinine in their bodies compared to people who smoke, indicating similar exposure to nicotine.3,4

18.5.8.2 Biomarkers of volatile organic compounds

Volatile organic compounds are carbon-based chemicals that easily evaporate into gases. Many of these chemicals are toxic and found in e-cigarette aerosols. Various studies have found consistent evidence suggesting that biomarkers of some volatile organic compounds (VOCs, such as acrylamide and acrylonitrile), and propylene glycol are higher in e-cigarette users compared with non-users. However, conflicting data meant that it is was unclear whether e-cigarette users have similar or higher biomarkers of acrolein, benzene, crotonaldehyde, formaldehyde, propylene oxide, toluene, xylene and 1,3-butadiene, and some metals compared to non-users.2,5

In comparisons of e-cigarette users to people who smoke conventional cigarettes: biomarkers of VOCs (acrolein, acrylamide, acrylonitrile, ethylene oxide, vinyl chloride and 1,3-butadiene) were lower in e-cigarette users. Other VOCs were detected but there was insufficient data to make comparisons (benzene, crotonaldehyde, xylene and propylene oxide).2,5 Biomarkers for toluene were relatively high in e-cigarette users.5

18.5.8.3 Biomarkers of toxic metal/metalloid exposure

Longitudinal studies have shown that people who use e-cigarettes (but not tobacco) have higher urinary levels of lead and cadmium compared to people who have never used these products.6,7 In adolescents, those who more frequently used e-cigarettes had higher levels of lead in their urine than those who used them less frequently.8  

Comparisons of lead and cadmium exposure between people who only smoke and those who only use e-cigarettes are inconsistent. One study found the levels of cadmium and lead were reduced in the blood of people who usually smoke but switched completely to e-cigarette use.9 However, two studies have found similar levels of these toxic metals in people who use cigarettes compared to e-cigarettes.10,11 Another study found e-cigarette users had lower levels of cadmium but similar levels of lead compared to people who smoke. This study also found similar levels of mercury, selenium and manganese.12 It should be noted that other sources of pollution will likely be contributing to the exposure of the metals.

18.5.8.4 Biomarkers of N-nitrosamine exposure

E-cigarettes do not contain tobacco, but most contain nicotine that is purified from tobacco plants. Tobacco-derived nicotine may contain small amounts of contaminating carcinogens (cancer-causing substances) from the tobacco. Biomarkers of tobacco-specific carcinogens NNN and NNAL have been detected in the saliva and other biofluids of e-cigarette users at higher levels compared to people who have never used e-cigarettes but lower levels than people who smoke tobacco.3,13,14

Related reading

Relevant news and research

A comprehensive compilation of news items and research published on this topic

Read more on this topic

Test your knowledge

References

1. US Department of Health and Human Services, A report of the Surgeon General: How tobacco smoke causes disease.: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK53017/.

2. Hiler M, Weidner AS, Hull LC, Kurti AN, and Mishina EV. Systemic biomarkers of exposure associated with ENDS use: a scoping review. Tobacco Control, 2023; 32(4):480-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34732539

3. McDonough SR, Rahman I, and Sundar IK. Recent updates on biomarkers of exposure and systemic toxicity in e-cigarette users and EVALI. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021; 320(5):L661-L79. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33501893

4. Stewart BW, Marshall H, Bonevski B, Griffin HJ, Hopkins AM, et al. The carcinogenicity of e-cigarettes: a qualitative risk assessment. Carcinogenesis, 2025; 47(1). Available from: https://www.ncbi.nlm.nih.gov/pubmed/41910510

5. Hammond D, Reid JL, Goniewicz ML, McNeill A, O'Connor RJ, et al. Biomarkers of toxicant exposure among youth in Canada, England, and the United States who vape and/or smoke tobacco or do neither. Cancer Epidemiology, Biomarkers & Prevention, 2025; 34(5):815-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39992176

6. Batista DR, Coelho LS, Tanni SE, and de Godoy I. Metal in biological samples from electronic cigarette users and those exposed to their second-hand aerosol: a narrative review. Frontiers in Medicine, 2024; 11:1349475. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38841573

7. Dai HD, Reyes S, Buckley J, and Maloney P. Biomarkers of nicotine and toxicant exposure by e-liquid nicotine concentration level among US adult exclusive e-cigarette users. Cancer Epidemiology, Biomarkers & Prevention, 2025; 34(1):42-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39387549

8. Kochvar A, Hao G, and Dai HD. Biomarkers of metal exposure in adolescent e-cigarette users: correlations with vaping frequency and flavouring. Tobacco Control, 2025; 34(5):579-84. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38684372

9. Prokopowicz A, Sobczak A, Szula-Chraplewska M, Ochota P, and Kosmider L. Exposure to cadmium and lead in cigarette smokers who switched to electronic cigarettes. Nicotine & Tobacco Research, 2019; 21(9):1198-205. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30107446

10. Xue Z, Orr-Souza E, Nargis N, Patel M, and Nighbor T. Nicotine and toxicant exposure among individuals using both combustible cigarettes and e-cigarettes based on level of product use. Nicotine & Tobacco Research, 2025; 27(9):1591-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40233071

11. Yuce Y and Can Eke B. Investigation of some metal levels in people using electronic cigarettes and IQOS. Toxicology Mechanisms and Methods, 2025; 35(8):1023-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40369841

12. Manietta L, Drake W, and Jayawardene W. Comparative analysis of inflammatory and heavy metal biomarkers in exclusive e-cigarette users, combustible tobacco users, and non-users aged 18-30: a cross-sectional NHANES analysis. Journal of Xenobiotics, 2025; 15(2). Available from: https://www.ncbi.nlm.nih.gov/pubmed/40278158

13. Melero-Ollonarte JL, Lidon-Moyano C, Perez-Ortuno R, Fu M, Ballbe M, et al. Specific biomarker comparison in current smokers, e-cigarette users, and non-smokers. Addictive Behaviors, 2023; 140:107616. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36680837

14. Taylor E, Simonavicius E, McNeill A, Brose LS, East K, et al. Exposure to tobacco-specific nitrosamines among people who vape, smoke, or do neither: a systematic review and meta-analysis. Nicotine & Tobacco Research, 2024; 26(3):257-69. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37619211

Intro
Chapter 2